United Therapeutics insider files Form 144 to sell 112,500 shares
Rhea-AI Filing Summary
United Therapeutics insider filed a Form 144 to sell 112,500 shares of common stock on 09/02/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing lists an aggregate market value of $34,285,500.00 and reports 45,226,262 shares outstanding. The shares were acquired the same day, 09/02/2025, by exercise of stock options and paid in cash. No securities were reported sold by the person in the prior three months, and the filer represents they have no undisclosed material adverse information.
Positive
- Filer provided required Rule 144 disclosure including broker, share count, acquisition method, and representation regarding material information
- No sales reported in the prior three months for the selling person, indicating this is a single disclosed transaction
Negative
- None.
Insights
TL;DR: Insider exercised options and intends to sell 112,500 shares worth $34.3M; routine disclosure with limited standalone market impact.
The filing shows a single transaction: exercise of stock options and proposed sale of 112,500 common shares on 09/02/2025 through Morgan Stanley Smith Barney LLC at an aggregate market value of $34,285,500. The filing reports 45,226,262 shares outstanding, providing context for scale. There are no reported sales by the person in the prior three months. This is a standard Rule 144 notice documenting a proposed sale rather than financial results or new corporate actions. From the filing alone, there is no additional operational or financial information disclosed.
TL;DR: The disclosure complies with Rule 144 reporting for an insider option exercise and sale; it includes the required representations and signatures.
The Form 144 contains the necessary elements: issuer and broker identification, class of securities, number of shares (112,500), acquisition method (exercise of stock options on 09/02/2025), payment in cash, and the filer’s representation about material non-public information. The filing notes no aggregated sales in the past three months. Based solely on the document, this is a routine compliance filing without governance changes or additional disclosures.